Le Lézard
Classified in: Health, Science and technology
Subject: Personnel

ReViral Announces Appointment of Alan Musso as Chief Financial Officer


ReViral Ltd., a clinical-stage company focused on developing novel, antiviral compounds that target respiratory syncytial virus (RSV), today announced the appointment of Alan A. Musso to the position of Chief Financial Officer, effective October 21, 2019. Mr. Musso, who brings more than 30 years of financial and operational leadership experience in both publicly-traded and private biopharma companies, will succeed Max Herrmann who will remain with the company in a consulting capacity to ensure a seamless transition.

"Alan is an exceptional addition to the ReViral team," said Alex C. Sapir, CEO of ReViral. "His distinguished track record of building finance and accounting organizations at several leading biopharma companies, along with his experience raising capital in both private and public settings will be invaluable as the company enters its next stage of development with our lead product, sisunatovir. I would also like to take this opportunity to thank Max for his hard work and dedication to ReViral over the past five years and am delighted that he has agreed to remain in a consulting capacity to ensure a seamless transition."

Mr. Musso joins ReViral from Peloton Therapeutics, Inc., a company focused on the discovery and development of novel small molecule therapeutics for the treatment of cancer. During his tenure as Chief Financial Officer and Treasurer at Peloton, the company completed a $150 million mezzanine financing and was poised for an initial public offering, when the company accepted an acquisition offer from Merck & Co. Prior to Peloton, Mr. Musso served as the Chief Financial Officer and Treasurer at several biopharmaceutical companies, including Bellicum Pharmaceuticals, Targacept, and Osiris Pharmaceuticals. Mr. Musso spent the early part of his career as a senior internal auditor at Pfizer as well as a Certified Public Accountant (CPA) at KPMG International. Mr. Musso received a B.S. in Accounting from Saint Mary's College of California, and a master's degree from the American Graduate School of International Management.

"I am delighted to be joining ReViral at such a dynamic time, as the company continues to build on its pipeline of innovative and life-changing treatments for RSV," said Mr. Musso. "I look forward to working with the ReViral team to bring our therapies to patients around the world."

Notes to Editors

About ReViral

ReViral is a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV). Founded in 2011, ReViral has an experienced R&D leadership team with a successful track record in antiviral drug discovery and development. The company has developed a novel antiviral programme targeting RSV fusion with highly potent, orally bioavailable inhibitors, strong drug-like characteristics and good pharmacokinetic properties offering versatility in the route of administration. The lead candidate, sisunatovir, completed a Phase 2a trial in adult volunteers, showing high potency and was well tolerated. The company also has an RSV replication programme at an earlier stage of development and plans to expand its pipeline. In July 2018, ReViral completed a $55 million Series B funding round from a group of leading venture capital investors jointly led by New Leaf Venture Partners and Novo Ventures, part of Novo Holdings A/S, with additional new investment from Perceptive Advisors. Existing investors Andera Partners, OrbiMed and Brace Pharma Capital also participated in the fundraising.

About Sisunatovir

Sisunatovir is an orally administered, small molecule fusion inhibitor being evaluated for the treatment of RSV. Sisunatovir blocks RSV replication by inhibiting RSV F-mediated fusion of RSV with the host cell. Preclinical tests showed sisunatovir to have an excellent toxicity profile with an attractive therapeutic index. In Phase 1 clinical studies, sisunatovir showed excellent exposure with no serious adverse events being reported. In 2018, sisunatovir generated positive results in a Phase 2a challenge trial in healthy adult volunteers, producing statistically significant reductions in viral load and clinical symptoms.

About Respiratory Syncytial Virus (RSV)

RSV is a pathogen that infects the human respiratory tract, potentially leading to bronchiolitis and pneumonia. While most (but not all) otherwise healthy people recover from the virus, there is an increased risk of severe disease and death in premature infants, individuals with certain pulmonary conditions, the elderly and those who are immune suppressed. In the United States, nearly all children become infected with RSV by age 2, with 75,000 to 125,000 of them hospitalized each year. Globally, RSV affects an estimated 64 million people and causes 160,000 deaths each year.

For more information, please visit http://www.reviral.co.uk


These press releases may also interest you

11 jui 2020
Samsung Biologics (207940.KS) has further expanded its partnership with STCube through an additional development and manufacturing service agreement of STM418, an anti-PD1 immuno-oncology candidate. STM418 received much attention from the biopharma...

11 jui 2020
As a gesture of gratitude to local public safety professionals working on the front lines of the COVID-19 pandemic, Premier Mortgage Resources, LLC, has launched a new home loan savings program, called "Hometown Heroes." Under this program, any first...

11 jui 2020
Burlington Medical, engineers of the highest quality and lightest weight radiation protection aprons in the industry, recently launched an advanced new core material for its Enviro-Lite® and Burlitetm products, made entirely in the U.S. The new core...

11 jui 2020
In lieu of an in-person update to the media, Dr. Howard Njoo, Canada's Deputy Chief Public Health Officer, issued the following statement on behalf of Dr. Theresa Tam, Canada's Chief Public Health Officer. "There have been 107,126 cases of COVID-19...

11 jui 2020
The latest data of the evolution of COVID-19 in Québec reveal 91 new cases over the past 24 hours, bringing the total number of people infected to 56,407. During the same period, 4 new deaths were recorded, to which are added 4 deaths that occurred...

11 jui 2020
Health Vector helps pharmaceutical companies engage with patients by supporting and empowering people along their unique life journeys. The versatile solution focuses on interventional and non-interventional studies, as well as post marketing...



News published on 21 october 2019 at 08:05 and distributed by: